Yen-Wen Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yen-Wen Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Diahn-Warng Perng
Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan ROC; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan ROC; Institute of Emergency and Critical Care Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan ROC
1 shared publication - Hsien-Tzung Liao
Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
1 shared publication - Hsin-Kuo Ko
Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
1 shared publication Jiang-Hwa Kao
Taipei Municipal Gan-Dau Hospital
1 shared publication- Kang-Cheng Su
Department of Chest Medicine Taipei Veterans General Hospital Taipei Taiwan, ROC
1 shared publication - Pei-Ku Chen
Taipei Municipal Gan-Dau Hospital
1 shared publication
Latest Publications
- Open Access
- 14 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3253
Unmet Need for Oral Corticosteroids Use and Exacerbations of Asthma in Primary Care in Taiwan
Patients with asthma are treated in primary healthcare facilities (PHCFs) in Taiwan, where the asthma control status associated with acute exacerbation (AE) and use of oral corticosteroids (OCS) and short-acting β2-agonist (SABA) inhalers remains unclear. A cross-sectional, close-ended, face-to-face questionnaire survey invited board-certified physicians who treat adult asthma patients in PHCFs. The contents of the questionnaire included three parts: rescue OCS to treat AE, regular OCS for asthma control, and AE-related adverse outcomes. There were 445 out of 500 physicians who completed the questionnaire, with 61% of them being non-pulmonologists. A substantial proportion of asthma patients needed rescue OCS or regular OCS each month, or ≥3 canisters of SABA inhalers per year. Approximately 86% of physicians reported their patients with ≥2 AE-related unscheduled visits to clinics or emergency departments in the past year. A total of 41% of physicians reported their patients receiving intubation or intensive care in the past year. A total of 92% of physicians prescribed rescue OCS ≤ 40 mg/day. A total of 92% of physicians prescribed rescue OCS for a duration of ≤7 days for AEs. A total of 85% of physicians prescribed regular OCS ≤ 10 mg/day for asthma control. This is the first study to present the perceptions of asthma-treating physicians on the use of OCS in PHCFs. In summary, 31% of physicians reported ≥ 6% of their patients needed OCS for asthma control and 41% of physicians reported their patients with adverse outcomes in the past year. Thus, the need to improve asthma control in Taiwan is suggested by our study results.
- 14 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3253
Open AccessUnmet Need for Oral Corticosteroids Use and Exacerbations of Asthma in Primary Care in Taiwan
Patients with asthma are treated in primary healthcare facilities (PHCFs) in Taiwan, where the asthma control status associated with acute exacerbation (AE) and use of oral corticosteroids (OCS) and short-acting β2-agonist (SABA) inhalers remains unclear. A cross-sectional, close-ended, face-to-face questionnaire survey invited board-certified physicians who treat adult asthma patients in PHCFs. The contents of the questionnaire included three parts: rescue OCS to treat AE, regular OCS for asthma control, and AE-related adverse outcomes. There were 445 out of 500 physicians who completed the questionnaire, with 61% of them being non-pulmonologists. A substantial proportion of asthma patients needed rescue OCS or regular OCS each month, or ≥3 canisters of SABA inhalers per year. Approximately 86% of physicians reported their patients with ≥2 AE-related unscheduled visits to clinics or emergency departments in the past year. A total of 41% of physicians reported their patients receiving intubation or intensive care in the past year. A total of 92% of physicians prescribed rescue OCS ≤ 40 mg/day. A total of 92% of physicians prescribed rescue OCS for a duration of ≤7 days for AEs. A total of 85% of physicians prescribed regular OCS ≤ 10 mg/day for asthma control. This is the first study to present the perceptions of asthma-treating physicians on the use of OCS in PHCFs. In summary, 31% of physicians reported ≥ 6% of their patients needed OCS for asthma control and 41% of physicians reported their patients with adverse outcomes in the past year. Thus, the need to improve asthma control in Taiwan is suggested by our study results.
- Open Access
- 19 September 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (9) , 1543-1544
Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS‐CoV‐2 infection in Taiwan
- 19 September 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (9) , 1543-1544
Open AccessTocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS‐CoV‐2 infection in Taiwan
- Open Access
- 17 September 2021
- Published by Springer Nature in Research Square
Hyperbaric Oxygen Therapy for the Adjunctive Treatment of Stroke Associated with Post-Cardiac Surgery Due To Native-Valve Endocarditis Infected by Cutibacterium Acnes: A Case Report
Background Stroke is an uncommon but significant complication of cardiac surgery. Cutibacterium (previously known as Propionibacterium) rarely causes infective endocarditis (IE), accounting for approximately 0.3% of all IE cases. Hyperbaric oxygen therapy (HBOT), involving the administration of 100% oxygen at a pressure of > 1.4 atmospheres absolute, increases the partial pressure of oxygen; therefore, it is recommended as an adjunctive treatment for stroke and some infections. However, there are no data supporting HBOT as an adjunctive therapeutic option for ischemic stroke related to post-cardiac surgery due to IE caused by Cutibacterium acnes. Case presentation: This study reports the case of an 68-year-old male patient who underwent cardiac surgery for native-valve IE caused by C. acnes. He underwent HBOT on postoperative day 11 for the treatment of ischemic stroke. The patient received 20 sessions of HBOT along with 6-week antimicrobial treatment with ceftriaxone and rehabilitation programs. Conclusions We have summarized the patient’s successful recovery and our clinical experience regarding the use of HBOT in our clinical setting. HBOT is an effective adjunctive therapeutic option for ischemic stroke related to post-cardiac surgery due to IE caused by C. acnes.
- 17 September 2021
- Published by Springer Nature in Research Square
Open AccessHyperbaric Oxygen Therapy for the Adjunctive Treatment of Stroke Associated with Post-Cardiac Surgery Due To Native-Valve Endocarditis Infected by Cutibacterium Acnes: A Case Report
Background Stroke is an uncommon but significant complication of cardiac surgery. Cutibacterium (previously known as Propionibacterium) rarely causes infective endocarditis (IE), accounting for approximately 0.3% of all IE cases. Hyperbaric oxygen therapy (HBOT), involving the administration of 100% oxygen at a pressure of > 1.4 atmospheres absolute, increases the partial pressure of oxygen; therefore, it is recommended as an adjunctive treatment for stroke and some infections. However, there are no data supporting HBOT as an adjunctive therapeutic option for ischemic stroke related to post-cardiac surgery due to IE caused by Cutibacterium acnes. Case presentation: This study reports the case of an 68-year-old male patient who underwent cardiac surgery for native-valve IE caused by C. acnes. He underwent HBOT on postoperative day 11 for the treatment of ischemic stroke. The patient received 20 sessions of HBOT along with 6-week antimicrobial treatment with ceftriaxone and rehabilitation programs. Conclusions We have summarized the patient’s successful recovery and our clinical experience regarding the use of HBOT in our clinical setting. HBOT is an effective adjunctive therapeutic option for ischemic stroke related to post-cardiac surgery due to IE caused by C. acnes.